Compare STC & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | STC | DFTX |
|---|---|---|
| Founded | 1893 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | STC | DFTX |
|---|---|---|
| Price | $61.02 | $20.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $81.33 | $40.25 |
| AVG Volume (30 Days) | 187.6K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | ★ 55.17 | N/A |
| EPS | ★ 4.05 | N/A |
| Revenue | ★ $2,921,636,000.00 | N/A |
| Revenue This Year | $13.62 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | $15.16 | ★ N/A |
| Revenue Growth | ★ 17.32 | N/A |
| 52 Week Low | $56.39 | $14.62 |
| 52 Week High | $78.61 | $21.10 |
| Indicator | STC | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 63.24 |
| Support Level | $60.08 | $16.41 |
| Resistance Level | $71.84 | N/A |
| Average True Range (ATR) | 1.92 | 1.09 |
| MACD | 0.29 | 0.23 |
| Stochastic Oscillator | 50.00 | 82.47 |
Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).